Highbridge Capital Management’s Tevogen Bio Holdings TVGN Stock Holding History

Highbridge Capital Management’s Portfolio TVGN Stock Details TVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-7,204	Closed	-$3.72M	–	485
2022 Q4	$3.72M	Sell	7,204 -17,792	-71%	-$9.1M	0.1%	195
2022 Q3	$12.7M	Buy	24,996 +2,404	+11%	+$1.21M	0.18%	152
2022 Q2	$11.3M	Sell	22,592 -2,984	-12%	-$1.49M	0.26%	135
2022 Q1	$12.8M	Buy	+25,576	New	+$12.7M	0.3%	96

Other funds holding TVGN

CCP

Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return

FCM

FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Highbridge Capital Management's TVGN Position: Q1 2023 in Review

Highbridge Capital Management sold out of Tevogen Bio Holdings (TVGN) in Q1 2023, closing a stake of 7,204 shares — an estimated $3.72M sold.

Highbridge Capital Management first reported a position in TVGN in Q1 2022 and held it in 4 quarters. The position peaked at $12.8M in Q1 2022. 4 funds tracked by Wall St. Rank hold TVGN as of Q1 2023.

Highbridge Capital Management reported no remaining Tevogen Bio Holdings position as of Q1 2023 after selling out during the quarter.
Highbridge Capital Management sold 7,204 Tevogen Bio Holdings shares in Q1 2023, an estimated $3.72M.
Highbridge Capital Management first reported a position in Tevogen Bio Holdings in Q1 2022 and held it in 4 quarters.
Highbridge Capital Management's Tevogen Bio Holdings position peaked at $12.8M in Q1 2022.
4 funds tracked by Wall St. Rank held Tevogen Bio Holdings as of Q1 2023.

Based on Highbridge Capital Management's 13F filing for Q1 2023, filed 11 May 2023.